Wouldn't it be wonderful to see our concerns resolved with:  

 -a sale

- a partnership proposal to move Apabetalone clinical development forward

- non-dilutive financing for Covid or BOM 2

I suspect that DM will double down on the Zenith opportunity to provide RVX funds to go it alone. This will be tempered with the statement that "We do not control the numerous Zenith trials and Zen-3694 final results continue to be pushed out - possibly late 2025 or mid 2026 - these trials take time and they are out of our control."

This vacuum of info is a reality - they have no solutions.

Please prove me wrong.

Chicagoest